ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented

Share Article

Clinical trial results for novel EGFR inhibitor AC0010 will be presented December 7th at World Conference on Lung Cancer.

News Image
We look forward to providing an update on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M resistance mutation

ACEA Biosciences, Inc. announced today that it will be presenting updated efficacy and safety data from its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th.

“We look forward to providing an update on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M resistance mutation,” said Dr. Xiao Xu, President and CEO of ACEA. “These interim data demonstrate the promising clinical activity and tolerability profile of AC0010 in the treatment of NSCLC. The availability of alternative treatment options like AC0010 will provide patients and physicians with flexibility as they tailor treatment regimens based on efficacy and tolerability.”

Presentation Detail
Abstract 5117 - Phase I/II Study of AC0010, Mutant­Selective EGFR Inhibitor, in Non­Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation. Presented by: Dr. Yi-Long Wu, MD, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH), and Guangdong Academy of Medical Sciences, Guangzhou/China.

  •     Session: MA16 - Novel Strategies in Targeted Therapy, Mini Oral Session
  •     Date and time: Dec 7, 2016 - 14:20 - 15:50 CET
  •     Location: Strauss 2

About AC0010
AC0010 is an orally available, irreversible small molecule tyrosine kinase inhibitor in development for the treatment of EGFR active and T790M mutations in NSCLC patients. In preclinical studies AC0010 has been found to selectively inhibit EGFR active (Exon 19 del, L858R) and T790M mutations up to 298-fold more efficiently than wild-type EGFR. Multiple clinical trials are currently underway in China and in the USA to demonstrate the clinical utility of AC0010 in NSCLC patients who have developed the EGFR 790M mutation. AC0010 is also being developed as a first-line therapy for treatment of the EGFR activating mutations Exon 19 del and L858R. ACEA holds worldwide rights for AC0010.

About ACEA Biosciences
ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company focused on the development and commercialization of innovative cell analysis instrumentation for life sciences, and on the discovery and development of novel pharmaceutical products for the treatment of chronic diseases. ACEA’s instruments, xCELLigence® and NovoCyte®, are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. More than 1,700 instruments have been placed globally, leading to >1,250 peer-reviewed publications from both academia and the pharmaceutical industry in diverse applications spanning everything from cancer immunotherapy and cardiotoxicity to chemotactic migration and GPCR inhibition. ACEA has leveraged its technology platform to develop a robust pipeline of clinical and preclinical small molecules for the treatment of cancer and autoimmune diseases, with two clinical stage programs running in China and the USA. ACEA Biosciences is headquartered in San Diego, California with world-class manufacturing operations in Hangzhou, China.

For more information on ACEA’s ongoing clinical trials, click here.

Source: ACEA Biosciences

ACEA Biosciences, Inc.
Xiao Xu

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Xue, Ph.D.
ACEA Biosciences, Inc.
+1 8587240928 Ext: 3075
Email >
Follow >
Follow us on
Visit website